Brief: Sensorion Announces Candidate Selection For GJB2 Gene Therapy Program

Sensorion SA

06/04/2023 06:38

April 6 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION ANNOUNCES CANDIDATE SELECTION FOR GJB2 GENE
THERAPY
PROGRAM
    * HOSTS RESEARCH AND DEVELOPMENT DAY SHOWCASING GENE THERAPY
FOR
INNER EAR DISEASES APRIL 6, 2023
    * THE CANDIDATE DESIGNED WITH A SPECIFIC ADENO-ASSOCIATED
VIRUS
(AAV) CAPSID TARGETS KEY CELLS IN THE EAR THAT NORMALLY EXPRESS
GJB2 AND AVOIDS OTOTOXICITY
    * SENSORION ALSO PLANS TO FILE A CLINICAL TRIAL APPLICATION
FOR
ITS OTOF-GT PROGRAM, A DUAL-VECTOR AAV GENE THERAPY PROGRAM

Source text for Eikon:  ID:nBw2YL5Vha 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))